Atea Pharmaceuticals (AVIR) Short Interest Ratio & Short Volume $3.44 0.00 (0.00%) (As of 09/27/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Atea Pharmaceuticals Short Interest DataAtea Pharmaceuticals (AVIR) has a short interest of 2.70 million shares, representing 3.65% of the float (the number of shares available for trading by the public). This marks a -4.59% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.4, indicating that it would take 11.4 days of the average trading volume of 323,452 shares to cover all short positions.Current Short Interest2,700,000 sharesPrevious Short Interest2,830,000 sharesChange Vs. Previous Month-4.59%Dollar Volume Sold Short$10.45 millionShort Interest Ratio11.4 Days to CoverLast Record DateSeptember 15, 2024Outstanding Shares84,420,000 sharesFloat Size74,010,000 sharesShort Percent of Float3.65%Today's Trading Volume140,453 sharesAverage Trading Volume323,452 sharesToday's Volume Vs. Average43% Short Selling Atea Pharmaceuticals? Sign up to receive the latest short interest report for Atea Pharmaceuticals and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartAVIR Short Interest Over TimeAVIR Days to Cover Over TimeAVIR Percentage of Float Shorted Over Time Ad Chaikin AnalyticsPrepare for an election day stock surpriseDuring his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential elections. But that's nothing compared to his new election stock warning.For all the details, including the #1 stock to SELL before Election Day, click here. Atea Pharmaceuticals Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 9/15/20242,700,000 shares $10.45 million -4.6%3.7%11.4 $3.87 8/31/20242,830,000 shares $10.90 million +13.7%3.8%12.1 $3.85 8/15/20242,490,000 shares $9.31 million +4.6%3.4%10.2 $3.74 7/31/20242,380,000 shares $9.09 million +0.4%3.2%9.2 $3.82 7/15/20242,370,000 shares $8.39 million +5.8%3.2%9.1 $3.54 6/30/20242,240,000 shares $7.41 million +5.2%3.0%8.7 $3.31 Get the Latest News and Ratings for AVIR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Atea Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 6/15/20242,130,000 shares $7.69 million -2.3%2.9%8.1 $3.61 5/31/20242,180,000 shares $8.00 million +16.6%3.0%7.6 $3.67 5/15/20241,870,000 shares $6.94 million +3.9%2.5%6 $3.71 4/30/20241,800,000 shares $6.66 million +2.9%2.4%5.2 $3.70 4/15/20241,750,000 shares $6.58 million +4.8%2.4%4.3 $3.76 3/31/20241,670,000 shares $6.75 million -1.8%2.3%3.6 $4.04 3/15/20241,700,000 shares $6.82 million +3.0%2.3%3.6 $4.01 2/29/20241,650,000 shares $7.11 million +1.9%2.2%3.4 $4.31 2/15/20241,620,000 shares $6.82 million -57.4%2.2%3.4 $4.21 1/31/20243,800,000 shares $15.81 million +1.9%5.2%8.1 $4.16 1/15/20243,730,000 shares $13.28 million -1.1%5.1%8.3 $3.56 12/31/20233,770,000 shares $11.50 million +7.1%5.1%9.1 $3.05 12/15/20233,520,000 shares $10.38 million -1.1%4.8%8.6 $2.95 11/30/20233,560,000 shares $10.64 million -1.7%4.9%8.8 $2.99 11/15/20233,620,000 shares $10.68 million +31.2%4.9%9.2 $2.95 10/31/20232,760,000 shares $8.97 million +15.0%3.8%7.2 $3.25 10/15/20232,400,000 shares $7.27 million +34.1%3.3%6.7 $3.03 9/30/20231,790,000 shares $5.37 million -6.8%2.4%5.3 $3.00 9/15/20231,920,000 shares $6.11 million +8.5%2.6%5.5 $3.18 8/31/20231,770,000 shares $5.95 million +4.7%2.4%5 $3.36 8/15/20231,690,000 shares $5.66 million -9.1%2.3%3.3 $3.35 7/31/20231,860,000 shares $6.38 million +1.6%2.5%2.8 $3.43 7/15/20231,830,000 shares $6.66 million +9.6%2.5%2.6 $3.64 6/30/20231,670,000 shares $6.25 million -8.2%2.3%2.3 $3.74 6/15/20231,820,000 shares $7.55 million -2.7%2.5%2.4 $4.15 5/31/20231,870,000 shares $7.46 million +9.4%2.6%2.3 $3.99 5/15/20231,710,000 shares $5.90 million -11.9%2.3%2.4 $3.45 4/30/20231,940,000 shares $6.34 million +2.1%2.7%3.5 $3.27 4/15/20231,900,000 shares $6.23 million +6.2%2.6%3.5 $3.28 3/31/20231,790,000 shares $6.00 million -5.8%2.5%3.4 $3.35 3/15/20231,900,000 shares $6.94 million +5.6%2.6%3.7 $3.65 2/28/20231,800,000 shares $6.37 million +20.0%2.5%4.2 $3.54 2/15/20231,500,000 shares $6.14 million +1.4%2.1%3.6 $4.09 1/31/20231,480,000 shares $6.85 million -10.8%2.0%3.2 $4.63Kamala’s tax plan is worse than you think—find out why (Ad)Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track record starts pulling out of the market, it's time to pay attention.Get your FREE, no-obligation Wealth Protection Guide now 1/15/20231,660,000 shares $8.18 million -0.6%2.3%3.6 $4.93 12/30/20221,670,000 shares $8.03 million -14.8%2.3%3.6 $4.81 12/15/20221,960,000 shares $8.60 million +3.2%2.7%4.1 $4.39 11/30/20221,900,000 shares $8.91 million -3.1%2.6%3.8 $4.69 11/15/20221,960,000 shares $10.15 million -13.7%2.7%3.9 $5.18 10/31/20222,270,000 shares $13.62 million -1.3%3.1%4.7 $6.00 10/15/20222,300,000 shares $12.08 million +4.1%3.1%5.2 $5.25 9/30/20222,210,000 shares $12.57 million -3.9%3.0%5 $5.69 9/15/20222,300,000 shares $15.76 million -12.9%3.1%4.9 $6.85 8/31/20222,640,000 shares $19.80 million -4.0%3.6%5.3 $7.50 8/15/20222,750,000 shares $23.60 million +1.1%3.8%4.8 $8.58 7/31/20222,720,000 shares $22.30 million -6.5%3.7%4 $8.20 7/15/20222,910,000 shares $23.57 million +10.7%4.0%4.2 $8.10 6/30/20222,630,000 shares $18.67 million +30.2%3.6%3.7 $7.10 6/15/20222,020,000 shares $13.33 million +4.1%2.8%2.7 $6.60 5/31/20221,940,000 shares $15.29 million -18.8%2.7%2.5 $7.88 5/15/20222,390,000 shares $17.42 million +21.9%3.3%2.9 $7.29 4/30/20221,960,000 shares $11.51 million +10.7%2.7%2.2 $5.87 4/15/20221,770,000 shares $11.66 million -15.3%2.5%1.8 $6.59 3/31/20222,090,000 shares $15.09 million -27.2%2.9%2 $7.22 3/15/20222,870,000 shares $16.33 million +11.2%4.0%2.5 $5.69 2/28/20222,580,000 shares $16.36 million +2.8%3.6%2 $6.34 2/15/20222,510,000 shares $16.11 million -20.1%3.5%1.8 $6.42 1/31/20223,140,000 shares $22.42 million +13.0%5.1%1.8 $7.14 1/15/20222,780,000 shares $20.29 million +6.9%4.5%1.4 $7.30 12/31/20212,600,000 shares $23.24 million +6.6%4.2%0.6 $8.94 12/15/20212,440,000 shares $19.52 million +29.8%3.9%0.5 $8.00 11/30/20211,880,000 shares $15.21 million -69.8%3.0%0.4 $8.09 11/15/20216,230,000 shares $71.65 million -0.6%10.0%1.3 $11.50 10/29/20216,270,000 shares $72.98 million +17.2%10.5%1.4 $11.64 10/15/20215,350,000 shares $210.15 million -17.3%8.9%1.3 $39.28 9/30/20216,470,000 shares $226.84 million +26.4%10.8%3.7 $35.06 9/15/20215,120,000 shares $133.02 million +0.6%8.8%3.7 $25.98 8/31/20215,090,000 shares $151.27 million -12.8%8.9%3.7 $29.72 8/13/20215,840,000 shares $161.59 million +9.2%10.6%4.4 $27.67 7/30/20215,350,000 shares $133.96 million -24.3%9.7%4.1 $25.04 7/15/20217,070,000 shares $155.61 million -18.6%12.9%5.1 $22.01 6/30/20218,690,000 shares $186.66 million +72.1%15.8%6.5 $21.48 6/15/20215,050,000 shares $119.08 million No Change9.2%5 $23.58 5/28/20215,050,000 shares $103.12 million +0.6%9.2%6.4 $20.42 5/14/20215,020,000 shares $96.48 million +5.5%9.1%7.2 $19.22 4/30/20214,760,000 shares $125.57 million +12.0%8.4%8 $26.38 4/15/20214,250,000 shares $231.97 million +36.7%9.3%12.2 $54.58 3/31/20213,110,000 shares $174.88 million +38.8%6.8%9.9 $56.23 3/15/20212,240,000 shares $152.01 million +34.9%4.9%6.8 $67.86 2/26/20211,660,000 shares $134.94 million +1.2%3.6%5 $81.29 2/12/20211,640,000 shares $144.19 million -27.8%3.7%5.3 $87.92 1/29/20212,270,000 shares $134.25 million No Change4.8%5.8 $59.14 1/15/20212,270,000 shares $118.27 million No Change4.8%4.8 $52.10 AVIR Short Interest - Frequently Asked Questions What is Atea Pharmaceuticals' current short interest? Short interest is the volume of Atea Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of September 15th, traders have sold 2,700,000 shares of AVIR short. 3.65% of Atea Pharmaceuticals' shares are currently sold short. Learn More on Atea Pharmaceuticals' current short interest. What is a good short interest ratio for Atea Pharmaceuticals? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. AVIR shares currently have a short interest ratio of 11.0. Learn More on Atea Pharmaceuticals's short interest ratio. What is a good short interest percentage for Atea Pharmaceuticals? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 3.65% of Atea Pharmaceuticals' floating shares are currently sold short. Is Atea Pharmaceuticals' short interest increasing or decreasing? Atea Pharmaceuticals saw a decrease in short interest in September. As of September 15th, there was short interest totaling 2,700,000 shares, a decrease of 4.6% from the previous total of 2,830,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Atea Pharmaceuticals' float size? Atea Pharmaceuticals currently has issued a total of 84,420,000 shares. Some of Atea Pharmaceuticals' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Atea Pharmaceuticals currently has a public float of 74,010,000 shares. How does Atea Pharmaceuticals' short interest compare to its competitors? 3.65% of Atea Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sector of "medical" compare to Atea Pharmaceuticals: Inovio Pharmaceuticals, Inc. (11.85%), Gyre Therapeutics, Inc. (1.31%), Disc Medicine, Inc. (9.02%), Spyre Therapeutics, Inc. (19.22%), Arcutis Biotherapeutics, Inc. (21.27%), Travere Therapeutics, Inc. (11.32%), Tectonic Therapeutic (0.72%), Cogent Biosciences, Inc. (10.18%), Praxis Precision Medicines, Inc. (11.59%), Bicycle Therapeutics plc (5.52%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Canadian Natural Resources Limited ($6.15 billion), Charter Communications, Inc. ($4.04 billion), Paychex, Inc. ($2.77 billion), Nu Holdings Ltd. ($2.71 billion), Cencora, Inc. ($2.34 billion), Aptiv PLC ($2.18 billion), Tractor Supply ($2.07 billion), International Paper ($2.01 billion), AppLovin Co. ($1.95 billion), and Moderna, Inc. ($1.89 billion). View all of the most shorted stocks. What does it mean to sell short Atea Pharmaceuticals stock? Short selling AVIR is an investing strategy that aims to generate trading profit from Atea Pharmaceuticals as its price is falling. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Atea Pharmaceuticals? A short squeeze for Atea Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of AVIR, which in turn drives the price of the stock up even further. How often is Atea Pharmaceuticals' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including AVIR, twice per month. The most recent reporting period available is September, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Inovio Pharmaceuticals Short Interest Gyre Therapeutics Short Interest Disc Medicine Short Interest Spyre Therapeutics Short Interest Arcutis Biotherapeutics Short Interest Travere Therapeutics Short Interest Tectonic Therapeutic Short Interest Cogent Biosciences Short Interest Praxis Precision Medicines Short Interest Bicycle Therapeutics Short Interest Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:AVIR) was last updated on 9/27/2024 by MarketBeat.com Staff From Our PartnersThe Bible Says it Clear As DayIt came to me clear-as-day thanks to the Bible… in the Parable of Talents, in the book of Matthew… This pa...Prosperity Research | Sponsored10X More Profitable Than Physical Gold?The smart money is piling into gold and gold stocks. There's a backdoor gold play that could deliver 10 TIM...Monument Traders Alliance | SponsoredPrepare for an election day stock surpriseDuring his 50 years on Wall Street, legendary stockpicker Marc Chaikin traded through 13 presidential election...Chaikin Analytics | SponsoredBuffett Dumps $982 Million in BofA Stock—What Does He Know?Buffett's been eerily quiet about his reasons, but his actions speak volumes. When someone with his track reco...Genesis Gold Group | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredFed Triggers Boom: Buy this Play on Elon’s New AIHave you seen Elon Musk's new invention? I was already very bullish on this new type of AI. And now that...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atea Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Atea Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.